On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science.

The publication titled ﾓA non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitisﾔ summarized the findings on the disease-suppressing effects of a non-inflammatory, nucleoside-modified mRNA vaccine in several clinically relevant mouse models of multiple sclerosis (MS).